How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Message received
Thanks again for rating us!
SEARCH
Sprint Bioscience: Proven Partnering Prowess
CB
RR
Christian Binder
Richard Ramanius
Redeye sees an improved outlook for Sprint Bioscience, as highlighted by its recently announced USD 277m licensing deal for oncology project Vps34. The pipeline of additional candidates for partnering bolsters our conviction. After a period of slow development for its partnered projects, the in our opinion modestly valued company is now in good shape, with its recently completed capital raise providing a solid runway until the next potential milestone payments.